Chul Kim
Hematology & Oncology · Washington, DCNPI 1841586302
Payments from drug & device makers
Across 421 payments — averaging $19,982 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim Pharma GmbH & Co.kg$2.2M
- Daiichi Sankyo Inc.$2M
- AstraZeneca$1.9M
- Boehringer Ingelheim$903K
- Janssen Research & Development, LLC$390K
- Regeneron$195K
- plus $752K from 28 others
Across 13 payments — averaging $1008.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$10K
- Regeneron$2K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$144,17683%
- Speaking & faculty fees$13,2378%
- Travel & lodging$10,8636%
- Food & beverage$4,7573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.kg | 24 | $2,209,216 |
| Daiichi Sankyo Inc. | 52 | $2,032,547 |
| AstraZeneca | 47 | $1,929,434 |
| Boehringer Ingelheim | 18 | $902,976 |
| Janssen Research & Development, LLC | 38 | $390,475 |
| Regeneron | 76 | $195,274 |
| Genentech, Inc. | 18 | $178,399 |
| Gilead | 1 | $156,538 |
| Novartis | 14 | $95,527 |
| Macrogenics, Inc. | 3 | $70,000 |
| Karyopharm Therapeutics Inc. | 1 | $61,525 |
| Blueprint Medicines Corporation | 3 | $35,350 |
| GSK | 7 | $32,937 |
| Johnson & Johnson | 27 | $17,273 |
| EMD Serono, Inc. | 5 | $16,662 |
| Boehringer Ingelheim International GmbH | 11 | $14,803 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $14,495 |
| Sanofi | 13 | $12,183 |
| E.r. Squibb & Sons, L.L.C. | 6 | $11,278 |
| Spectrum Pharmaceuticals Inc. | 1 | $9,747 |
| Janssen Scientific Affairs, LLC | 7 | $7,805 |
| Bayer | 4 | $4,453 |
| Partner Therapeutics, Inc. | 10 | $4,418 |
| Jazz Pharmaceuticals Inc. | 1 | $3,200 |
| Astrazeneca UK Limited | 1 | $1,900 |
| Pfizer | 1 | $1,300 |
| Boehringer Ingelheim Espana S.A. | 17 | $1,260 |
| Eisai Inc. | 1 | $645 |
| Novocure Inc. | 2 | $203 |
| Caris MPI, Inc. | 1 | $191 |
| Regeneron Healthcare Solutions, Inc. | 3 | $137 |
| Amgen | 2 | $116 |
| Genentech USA, Inc. | 2 | $46 |
| Angiodynamics, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,412,345 in reported general payments places this provider in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 57 | $954,316 |
| EliquisApixaban | 39 | $25,277 |
| Enoxaparin Sodium | 13 | $3,991 |
| Erlotinib Hcl | 22 | $2,770 |
| Oxycodone Hcl | 46 | $528 |
| Ondansetron Hcl | 37 | $514 |
| Dexamethasone | 26 | $455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $350 |
| Gabapentin | 31 | $332 |
| Prochlorperazine Maleate | 16 | $260 |
| Pantoprazole Sodium | 12 | $177 |
| Hydrocortisone | 23 | $154 |
| Atorvastatin Calcium | 18 | $121 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $120 |
| Prednisone | 50 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $1,929,434 | $954,31657 claims |
| PfizerEliquis | $1,300 | $25,27739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Pavani ChalasaniWashington$10.3M
- Vered StearnsWashington$7.8M
- Benjamin WeinbergWashington$7.3M
- Claudine IsaacsWashington$5.3M
- Julie BaumanWashington$3.4M
- Catherine BroomeWashington$2.9M
- Suthee RapisuwonWashington$1.9M
- Julie CollinsWashington$1.8M
- Ami ChitaliaWashington$1.8M
- Imadeddine TabbaraWashington$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.